Transurethral microwave hyperthermia for benign prostatic hyperplasia: preliminary clinical and pathological results.
Transurethral microwave hyperthermia is a new conservative treatment modality for benign prostatic hyperplasia. We treated 15 patients with 915 MHz. microwaves delivered transurethrally by a helical applicator. Of the patients 12 showed substantial objective and subjective improvement of obstructive outflow parameters. Significant improvement in objective study parameters included increased mean flow rate (p less than 0.00021), decreased mean residual volume (p less than 0.00001) and decreased mean prostatic volume (p less than 0.0077). Analysis of patterns of failure showed chronic bladder atony, prostate asymmetry and middle lobe configuration as important factors that could explain the failure of hyperthermia in 3 patients. Toxicity was mild, consisting of bladder spasms, perineal pain, dysuria and hematuria. Hyperthermia-induced pathological changes in prostatic tissues, causing periurethral shrinking and secondary dilatation of the prostatic urethra, are described. The reported clinical results of this phase I study are preliminary due to the short followup. A phase II study to optimize transurethral hyperthermia currently is underway. A phase III study is to be phased in comparing hyperthermia with transurethral resection of the prostate.
Baert
O
O
Department of Urology, University Hospital St. Pieter, Catholic University of Leuven, Belgium.
Ameye
F
F
Willemen
P
P
Vandenhove
J
J
Lauweryns
J
J
Astrahan
M
M
Petrovich
Z
Z
D000368:Aged; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008872:Microwaves / Q000627:therapeutic use*; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000628:therapy*